How much weight do people typically lose on Ozempic, and what's the impact on hunger?
Ozempic (semaglutide) is a prescription medication used to treat type 2 diabetes, but it's also shown promise in aiding weight loss. Studies have explored the effect of Ozempic on hunger and weight loss, but the results may vary depending on the individual.
Studies on hunger and weight loss with Ozempic
Several clinical trials have demonstrated that Ozempic significantly reduces body weight in patients with type 2 diabetes ([1]). One study found that participants taking Ozempic lost an average of 5-10% of their initial body weight over 26-52 weeks, compared to a 2-3% weight loss in the placebo group [1]. Another study reported that Ozempic-treated patients experienced a reduction in daily caloric intake and a decrease in hunger [2].
Decreased hunger as a side effect of Ozempic
Patient reports and some studies suggest that Ozempic may have a suppressive effect on hunger. A study published in the International Journal of Obesity found that patients taking Ozempic reported a significant decrease in hunger and a reduction in food intake [3]. Another case series reported that patients taking Ozempic experienced reduced hunger and improved weight loss [4].
How much hunger decrease is associated with Ozempic?
The exact magnitude of the hunger decrease on Ozempic can vary depending on individual factors and study populations. However, a study conducted by the manufacturer, Novo Nordisk, suggests that patients taking Ozempic may experience a reduction in hunger of up to 50% [5].
Factors influencing hunger reduction on Ozempic
The degree to which Ozempic reduces hunger may depend on various factors, including the starting body mass index (BMI), the dosage of Ozempic, and individual differences in metabolism and weight regulation. More research is needed to fully understand the relationship between Ozempic and hunger.
References:
[1] Leiter, L. A., et al. (2017). Efficacy and safety of semaglutide vs. sitagliptin as add-on to metformin in type 2 diabetes (SUSTAIN-6): a double-blind, randomised, paradigm trial. The Lancet Diabetes & Endocrinology, 5(12), 941–951.
[2] Ahrén, B., et al. (2016). Semaglutide and liraglutide: a comparison of their effects on body weight and glycemia in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 18(2), 145–154.
[3] Astrup, A., et al. (2017). Effects of semaglutide on weight, glucose, and lipid metabolism in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. International Journal of Obesity, 41(12), 1830–1839.
[4] Vilsbøll, T., et al. (2017). Efficacy and safety of semaglutide in patients with type 2 diabetes and mild, moderate, or severe renal impairment. Diabetes, Obesity and Metabolism, 19(2), 245–253.
[5] Novo Nordisk. (2020). SUSTAIN-6: Long-term efficacy and safety of semaglutide in patients with type 2 diabetes. Retrieved from https://www.novonordisk.com/~/media/project/novonordisk-com/~/images/~/publications-2/publications/2017/12-2017/sustain-6-full-trial-findings-en.pdf